| Particulars (Rupees in Crores.) | Mar-2025 | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 |
|---|---|---|---|---|---|
Gross Sales | 1,961.7 | 1,680.7 | 1,770.4 | 1,718.2 | 1,780.3 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,961.7 | 1,680.7 | 1,770.4 | 1,718.2 | 1,780.3 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 37.2 | 66.6 | 45.4 | 45.2 | 40 |
Total Income | 1,998.9 | 1,747.3 | 1,815.8 | 1,763.4 | 1,820.3 |
Total Expenditure | 1,334.5 | 1,266.1 | 1,225.7 | 1,259.6 | 1,235.2 |
PBIDT | 664.4 | 481.2 | 590.1 | 503.8 | 585.1 |
Interest | 28.3 | 24.8 | 23.7 | 23.5 | 24.1 |
PBDT | 636.1 | 456.4 | 566.4 | 480.3 | 561 |
Depreciation | 214.8 | 217.8 | 219.2 | 206.7 | 190.2 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 91.8 | 46.6 | 66.9 | 56.1 | 59.2 |
Deferred Tax | 15.1 | 10.2 | -19.8 | 7.6 | 23.1 |
Reported Profit After Tax | 314.4 | 181.8 | 300.1 | 209.9 | 288.5 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 314.4 | 181.8 | 300.1 | 209.9 | 288.5 |
Extra-ordinary Items | 0 | 24.38 | -3.7 | -5.68 | 0 |
Adjusted Profit After Extra-ordinary item | 314.4 | 157.42 | 303.8 | 215.58 | 288.5 |
EPS (Unit Curr.) | 7.81 | 4.53 | 7.47 | 5.23 | 7.19 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 402.5 | 402.5 | 402 | 402 | 401.4 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 33.86 | 28.63 | 33.33 | 29.32 | 32.86 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 16.02 | 10.81 | 16.95 | 12.21 | 16.2 |
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
